ProvideGx to hike production of 5 generic injectables in short supply

ProvideGx, a subsidiary of Premier, will collaborate with Fresenius Kabi to help mitigate national shortages of five generic injectable medications.

Advertisement

The two companies will boost production of injectable thiamine, lidocaine, diphenhydramine, hydromorphone and morphine sulfate.

ProvideGx was established by Premier in January to address supply shortages plaguing health systems across the U.S.

The company plans to work with generic drug manufacturers, co-fund development of affordable products and secure contracts for active pharmaceutical ingredients to ensure supply demands are met. ProvideGx will begin with drugs from a target list of more than 60 that are in short supply.

The financial terms of the collaboration with Fresenius were not disclosed.

More articles on pharmacy:
8 recent pharmaceutical lawsuits, settlements
McKesson renews distribution deal with CVS Health
Sacklers discussed selling Purdue Pharma in 2000, court documents reveal

At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.

Advertisement

Next Up in Pharmacy

Advertisement

Comments are closed.